Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/107084
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Vieira, Raquel | - |
dc.contributor.author | Souto, Selma B. | - |
dc.contributor.author | Sánchez-López, Elena | - |
dc.contributor.author | Machado, Ana López | - |
dc.contributor.author | Severino, Patrícia | - |
dc.contributor.author | Jose, Sajan | - |
dc.contributor.author | Santini, Antonello | - |
dc.contributor.author | Fortuna, Ana | - |
dc.contributor.author | García, Maria Luisa | - |
dc.contributor.author | Souto, Eliana B. | - |
dc.date.accessioned | 2023-05-11T12:15:05Z | - |
dc.date.available | 2023-05-11T12:15:05Z | - |
dc.date.issued | 2019-08-28 | - |
dc.identifier.issn | 2077-0383 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/107084 | - |
dc.description.abstract | Diabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic β-cell destruction depriving the organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the animal model should be carefully selected among the wide variety of the currently available ones. This review discusses the most common animal models currently employed to study T1DM and T2DM. Moreover, an overview on the administration routes that could be used is also discussed. | pt |
dc.language.iso | eng | pt |
dc.publisher | MDPI | pt |
dc.relation | M-ERA-NET/0004/2015-PAIRED | pt |
dc.relation | Institute of Nanoscience and Nanotechnology under the project ART (2018) | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt |
dc.subject | diabetes mellitus | pt |
dc.subject | animal models | pt |
dc.subject | in vivo | pt |
dc.subject | administration routes | pt |
dc.title | Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II | pt |
dc.type | article | - |
degois.publication.firstPage | 1332 | pt |
degois.publication.issue | 9 | pt |
degois.publication.title | Journal of Clinical Medicine | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.3390/jcm8091332 | pt |
degois.publication.volume | 8 | pt |
dc.date.embargo | 2019-08-28 | * |
uc.date.periodoEmbargo | 0 | pt |
item.languageiso639-1 | en | - |
item.grantfulltext | open | - |
item.fulltext | Com Texto completo | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.openairetype | article | - |
item.cerifentitytype | Publications | - |
crisitem.author.orcid | 0000-0001-5652-9219 | - |
crisitem.author.orcid | 0000-0003-2571-108X | - |
crisitem.author.orcid | 0000-0001-6527-6612 | - |
crisitem.author.orcid | 0000-0002-9737-6017 | - |
Appears in Collections: | FFUC- Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Sugarlowering-drugs-for-type-2-diabetes-mellitus-and-metabolic-syndromestrategies-for-in-vivo-administration-PartIIJournal-of-Clinical-Medicine.pdf | 581.4 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
50
checked on Sep 2, 2024
WEB OF SCIENCETM
Citations
42
checked on Sep 2, 2024
Page view(s)
75
checked on Sep 10, 2024
Download(s)
19
checked on Sep 10, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License